How do I transition from active treatment to surveillance for Ovarian Cancer

Transitioning from Active Treatment to Surveillance for Ovarian Cancer

This is an important question that many ovarian cancer patients face. Let me help you understand this transition and what questions to ask your care team.

Understanding the Transition Framework

The transition from active treatment to surveillance (also called "active surveillance" or monitoring) is a significant shift in your cancer care approach. Rather than receiving chemotherapy or other active treatments on a regular schedule, you'll move to a monitoring-focused approach where your medical team watches for any signs of cancer recurrence.

According to guidance from cancer care experts, the key principle is timing: surveillance typically begins when your cancer has responded well to treatment and you've completed your planned therapy course. Your oncologist will establish a monitoring schedule based on your specific situation.

What "Surveillance" Actually Means

Surveillance involves regular check-ups and tests to detect any early signs of cancer returning. This typically includes:

• Physical exams with your oncologist
• Blood tests (CA-125 levels, which can indicate ovarian cancer activity)
• Imaging studies (CT scans, ultrasounds) on a scheduled basis
• Symptom monitoring - paying attention to new or unusual symptoms between appointments

According to the webinar on "Identifying the Most Effective Treatment on the Tumor Rather than Trying It Out on the Patient" (Dr. [removed] Apfel), ovarian cancer oncologists and surgeons are particularly engaged in precision medicine approaches. The guidance notes that for gynecological cancers like ovarian cancer, doctors often have access to tissue and understand the importance of molecular profiling to inform future treatment decisions if needed.

The Clinical Reasoning Behind Surveillance

Your oncology team considers several factors when deciding if you're ready for surveillance:

1. Response to treatment - Did your cancer shrink significantly?
2. Completion of planned therapy - Have you finished your chemotherapy or targeted therapy course?
3. Overall health status - Can you tolerate the monitoring schedule?
4. Tumor characteristics - Does your cancer's molecular profile suggest a good prognosis?
5. Your preferences - How do you feel about transitioning to monitoring versus continuing treatment?

Important Monitoring Considerations

Liquid Biopsies and Advanced Monitoring:

According to the webinar "Liquid Biopsies" (Peter Kuhn and Stephanie Shishido), emerging blood tests called "liquid biopsies" can detect circulating tumor DNA (ctDNA) - cancer cells or DNA fragments in your bloodstream. These tests may help detect recurrence earlier than traditional imaging. However, an important caveat: detecting something earlier doesn't automatically mean better outcomes unless there's an effective treatment available to use at that earlier time.

For ovarian cancer specifically, liquid biopsies could potentially:

• Provide earlier warning of recurrence
• Help guide decisions about when to restart treatment
• Monitor your response during surveillance

Timing of Testing:

The guidance emphasizes that testing should be done at strategic times - particularly when you're planning to make treatment changes. During stable surveillance, your team will establish a regular testing schedule (often every 3 months initially, then potentially spacing out over time).

Key Questions to Ask Your Oncology Team

As you transition to surveillance, ask your doctor:

1. "What specific tests will I have during surveillance, and how often?"

   • How frequently will I have CT scans or ultrasounds?
   • How often will I have blood work (CA-125)?
   • Will you consider liquid biopsy testing for me?

2. "What are the signs or symptoms that would prompt me to contact you between appointments?"

   • What abdominal or pelvic symptoms should concern me?
   • When should I call versus waiting for my next appointment?

3. "What is my CA-125 baseline, and what level would trigger further investigation?"

   • Normal CA-125 varies, but rising levels can indicate recurrence
   • Understanding your personal baseline is important

4. "If my cancer recurs, what treatment options would you consider?"

   • Would I receive the same chemotherapy again?
   • Are there new targeted therapies or clinical trials available?
   • Do you recommend any molecular testing now to guide future decisions?

5. "How long will surveillance typically continue?"

   • Is there a timeframe after which recurrence becomes less likely?
   • Will the monitoring schedule change over time?

6. "Should I consider any additional molecular testing now while I'm in remission?"

   • Could comprehensive genomic profiling help guide future treatment?
   • Would BRCA testing (if not already done) be relevant?
   • Are there other biomarkers that would be helpful to know?

7. "What role might clinical trials play if my cancer recurs?"

   • Should I be aware of any trials now that might be relevant later?

The Psychological Aspect

According to the webinar "An MD PhD Navigates Breast Cancer" (Catalina Lopez-Correa, MD, PhD), the transition to surveillance can bring mixed emotions. Some patients experience relief at completing active treatment, while others feel anxiety about "doing nothing." This is completely normal. The key is understanding that surveillance IS active care - you're actively monitoring for recurrence, not passively waiting.

Preparing for Surveillance Success

Before you transition:

• Get a clear written summary of your treatment history
• Understand your tumor's specific characteristics (stage, grade, molecular markers)
• Establish a regular appointment schedule with your oncologist
• Know how to reach your care team between appointments
• Consider joining an ovarian cancer support group

During surveillance:

• Keep detailed records of any symptoms or changes
• Don't skip scheduled appointments or tests
• Be honest about side effects from prior treatment that may still be affecting you
• Stay informed about new ovarian cancer research and treatment options

Important Reminder

Your specific surveillance plan should be individualized based on your cancer stage, grade, molecular characteristics, treatment response, and overall health. The NCCN Guidelines and ASCO (American Society of Clinical Oncology) provide evidence-based recommendations, but your oncologist will tailor the approach to YOUR specific situation.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.